![\"\"](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/08\/DRMTO-082626-Alopecia.jpg\"\/)
<\/p>\n<\/p>\n
Credit: istock.com\/NadiiaMoiseyenko<\/p>\n
According to a systemic review and meta-analysis, oral Janus kinase (JAK) inhibitors showed efficacy in the regrowth of scalp, eyebrow, and eyelash hair among adult and adolescent patients with moderate-to-severe alopecia areata.<\/p>\n
Within the past decade, JAK inhibitors have become a therapeutic option for patients with alopecia areata, a population that has historically lacked effective treatments for moderate to severe disease. With a number of JAK inhibitors approved in this landscape and randomized clinical trials conducted, Samuel Morriss, MD, from The Royal Melbourne Hospital, in Melbourne, Victoria, Australia, and colleagues sought to compare efficacy and safety outcomes of oral JAK inhibitors with placebo for patients with moderate-to-severe alopecia areata.<\/p>\n
Twelve randomized clinical trials were included from MEDLINE (Ovid), Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), with 4,141 patients aged 12 years or older (11 trials enrolled only adults, while one trial had a study population in which 15% were adolescents). All trials evaluated the efficacy and safety of JAK inhibitors in alopecia areata. JAK inhibitors that were investigated included baricitinib, deuruxolitinib, ritlecitinib, brepocitinib, ivarmacritinib, and tofacitinib. The primary outcomes were the proportion of patients who achieved more than a 10% or 20% improvement in Severity of Alopecia Tool (SALT) score from baseline (SALT \u226410, SALT \u226420), as well as those who achieved SALT50, SALT75, and SALT90, and treatment-related adverse events.<\/p>\n
Across six randomized clinical trials, more patients receiving JAK inhibitors achieved SALT less than or equal to 10, than placebo at week 24 (odds ratio [OR], 5.69). In three trials extending to week 36, the same effect was increased (OR, 9.40). Two trials showed more patients who received JAK inhibitors achieved SALT less than or equal to 20 compared with placebo from week 12 to week 16 (OR, 5.03). This effect was durable in eight trials at week 24 (OR, 7.99) and in three trials at week 36 (OR, 8.75). In three trials, more patients on JAK inhibitors achieved SALT50 compared with placebo at week 12 (OR, 4.96), which was maintained in four trials at week 24 (OR, 4.56). In three trials, the odds of patients achieving SALT90 were more than 10 times greater among those receiving JAK inhibitors than those receiving placebo (OR, 10.11).<\/p>\n
Across all 12 trials, JAK inhibitors were associated with a higher risk for total adverse events when compared to placebo or azathioprine. The difference in rate of severe adverse events, serious adverse events, and treatment discontinuations due to adverse events was not significantly different between JAK inhibitors and placebo.<\/p>\n
While Dr. Morriss and colleagues concluded \u201cthese results strengthen the evidence base for oral JAK inhibitors as an effective systemic therapy for moderate-to-severe [alopecia areata],\u201d they went on to underscore \u201cthe need for comparative trials and standardization of outcome measures.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Credit: istock.com\/NadiiaMoiseyenko According to a systemic review and meta-analysis, oral Janus kinase (JAK) inhibitors showed efficacy in the…\n","protected":false},"author":2,"featured_media":872303,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[49,48,84],"class_list":["post-872302","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-ca","tag-canada","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/872302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=872302"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/872302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/872303"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=872302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=872302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=872302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}